Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГНЦ социальной и судебной психиатрии им. В.П.Сербского, Москва
Список исп. литературыСкрыть список 1. Аведисова А.С. Появится ли альтернатива бензодиазепинам? Психиатр. и психофармакотер. 2006; 11 (2). http://consilium-medicum.com/magazines/special/psychiatry/article/10960 2. Аведисова А.С., Ястребов Д.В., Алкеева-Костычева Е.А. Расстройства, возникающие при отмене бензодиазепиновых транквилизаторов. Психиатр. и психофармакотер. 2006; 8 (5): 20–3. 3. Авруцкий Г.Я., Вовин Я.Р., Личко А.Е., Смулевич А.Б. Биологическая терапия психических заболеваний. Л.: Медицина, 1975. 4. Мосолов С.Н. Основы психофармакотерапии. М., 1996. 5. Смулевич А.В., Дробижев М.Ю., Иванов С.В. Транквилизаторы – производные бензодиазепина в психиатрии и общей медицине. М., 1999. 6. Хруленко-Варницкий И.О. Особенности терапевтического действия феназепама при невротических расстройствах у больных с преобладанием возбудимых и тормозимых индивидуально-типологи- ческих черт. В кн.: Новое в терапии и организации помощи больным с пограничными нервно-психическими расстройствами. М., 1986; с. 56–8. 7. Ястребов Д.В., Алкеева-Костычева Е.А. Эффективность различных вариантов отмены бензодиазепиновых транквилизаторов, принимаемых в терапевтических дозах. Рос. психиатр. журн. 2008; 1: 67–74. 8. Davidson JR. Continuation treatment of panic disorder with high-potency benzodiazepines. J Clin Psychiat 1990; 51 (Suppl. A): 31–7. 9. Ditch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiat 1988; 49: 184–8. 10. Fawcett JA, Kravitz HM. Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. Pharmacother 1982; 2: 243–54. 11. Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988; 18: 365–74. 12. Gonzalez ER. Panic disorder may respond to new «antidepressants». JAMA 1982; 248: 3077–87. 13. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiat 2003; 64 (Suppl. 2): 24–9. 14. Higgitt AC, Lader MH, Fonagy P. Clinical management of benzodiazepine dependence. Br Med J 1985; 291: 688–90. 15. Ishigooka J, Sugiyama T, Suzuki M et al. Survival analytic approach to long-term prescription of benzodiazepine hypnotics. Psychiat and Clin Neurosciences 1998; 52: 541–5. 16. Kroboth PD, Smith RB, Erb RJ. Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharmacol Ther 1988; 43: 270–7. 17. Lupolover R, Dazzi H, Ward J. Rebound phenomena: results of a 10 year (1970–1980) literature review. Int Pharmacopsychiat 1982; 17 (4): 194–237. 18. Lydiard RB, Rickels K, Herman B, Feltner E. Pregabalin for psychic and somatic symptoms of GAD. International J Neuropsychopharmacol 2010; 13: 229–41. 19. Marks J. The benzodiazepines: use, overuse, misuse, abuse. Lancaster UK: MTP 1978. 20. Miller W. Addictive behaviors: treatment of alcoholism, drug abuse, smoking and obesity. Oxford: Pergamon Press 1984. 21. von Moltke L, Greenblatt DJ, Cotreau-Bibbo MM et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmac 1994; 38: 23–31. 22. Nash JR, Nutt DJ. Pharmacotherapy of anxiety. In: Handbook of experimental pharmacology. Anxiety and anxiolytic drugs. Ed.: F.Holsboer, A.Ströhle. Springer 2005; 169: 469–502. 23. Nikaido AM, Ellinwood EH. Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance. Psychopharmacol 1987; 92: 459–64. 24. Petursson H, Lader M. Dependence on tranquilizers. Oxford University Press 1984. 25. Rocca P, Fonzo V, Scotta M et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95: 444–50. 26. Salzman С. Behavioral side effects of benzodiazepines. In: J.Kane, J.Lieberman. Adverse effects of psychotropic drugs. NY: Guilford Press 1992. 27. Smith RB, Kroboth PD, Vanderlught JT et al. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacol 1984; 84: 452–6. 28. Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacol 1987; 93: 105–12. 29. Soumerai SB, Simoni-Wastla L, Singer C et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatric Services 2003; 54 (7): 1006–11. 30. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutics use for benzodiazepines. Effects of gradual taper. Arch Gen Psychiat 1990; 47: 908–15. 31. Tyrer P. Dependence as a limiting factor in the clinical use of minor tranquilisers. Pharmacol Ther 1988; 36: 173–188. 32. Verster JC, Volkerts EV. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Reviews 2004; 10 (1): 45–76. 33. Wysowski DK, Barash D. Adverse behavioral reactions attributed to triazolam in the food and drug administration\'s spontaneous reporting system. Arch Intern Med 1991; 151: 2003–8.